Atossa Therapeutics

Our clinical trial has a website now.

Breast Cancer Clinical Trial | Evangeline The Evangeline once-a-day oral capsule breast cancer clinical trial for premenopausal women is now enrolling in multiple sites around the US. Enroll Now.

Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update - Atossa Therapeutics SEATTLE, March 22, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in cancer, today announced financial results for the fiscal quarter and fiscal year ended De...

Atossa Doses First Patient in Phase 2 Neoadjuvant Clinical Study of (Z)-Endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer - Atossa Therapeutics SEATTLE, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet need in cancer, today announces that the first patient has been dosed in the Phase 2 EVANGELINE (En...

Atossa Therapeutics Further Strengthens Intellectual Property Portfolio with Additional Broad Patent for Endoxifen - Atossa Therapeutics SEATTLE, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet need in cancer, today announces that the United States Patent and Trademark Office (USPTO) has gran...

Atossa Therapeutics, Inc. to Acquire Stake in Privately Held Dynamic Cell Therapies as Part of Overall CAR-T Strategy - Atossa Therapeutics SEATTLE, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), announces today that it is investing in privately-held developer of CAR-T therapies, Dynamic Cell Therapies, Inc. (DCT). Atossa is a clinical-stage biopharmaceutical company seeking to develop innovative medicines i...